Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets and ASC30 Tablets A1 in Participants With Obesity or Overweight With Weight-Related Comorbidities

NCT07002905 is registered in ClinicalTrials.gov with Ascletis Pharma (China) Co., Limited as lead sponsor.

NCT NCT07002905
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07002905 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets and ASC30 Tablets A1 in Participants With Obesity or Overweight With Weight-Related Comorbidities
Lead sponsor
Ascletis Pharma (China) Co., Limited
Phase
Phase 2
Overall status
Completed
Start date
July 3, 2025
Completion date
December 8, 2025
Enrollment
125 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

chronic weight management